Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

This study has been completed.
Information provided by:
Tripler Army Medical Center
ClinicalTrials.gov Identifier:
First received: September 8, 2005
Last updated: February 25, 2010
Last verified: March 2004
This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. The investigators will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.

Condition Intervention
Ovarian Neoplasms
Procedure: removal of ovarian vessels

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms

Resource links provided by NLM:

Further study details as provided by Tripler Army Medical Center:

Primary Outcome Measures:
  • Compare the levels of AVP and the vasopressin V1 receptor expression in the arteries and veins of ovarian tissue found to be cancerous versus ovarian tissue found to be noncancerous
  • Correlate the expression of AVP and its V1 receptor to stage of ovarian neoplasms graded by histology assessment
  • Correlate the expression of AVP and its receptor to intratumoral vascularization through Doppler ultrasound and systemic blood pressure.

Estimated Enrollment: 110
Study Start Date: March 2004
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.

Exclusion Criteria:

  • Patients who have a malignancy that is not a primary gynecologic malignancy.
  • Age less than 18
  • Males
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00160472

United States, Hawaii
Tripler Army Medical Center
Honolulu, Hawaii, United States, 96859
Sponsors and Collaborators
United States Department of Defense
Principal Investigator: John H Farley, MD Uniformed Services Unievrsity of the Health Sciences
  More Information

ClinicalTrials.gov Identifier: NCT00160472     History of Changes
Other Study ID Numbers: TAMC 3H04 
Study First Received: September 8, 2005
Last Updated: February 25, 2010
Health Authority: United States: Federal Government

Keywords provided by Tripler Army Medical Center:

Additional relevant MeSH terms:
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Arginine Vasopressin
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on May 23, 2016